发明名称 Macrocyclic hepatitis C serine protease inhibitors
摘要 The present invention relates to compounds of Formula I, II or Ill, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: wherein W is a substituted or unsubstituted heterocyclic ring system. The compounds inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
申请公布号 US7601709(B2) 申请公布日期 2009.10.13
申请号 US20040774047 申请日期 2004.02.06
申请人 ENANTA PHARMACEUTICALS, INC. 发明人 MIAO ZHENWEI;SUN YING;NAKAJIMA SUANNE;TANG DATONG;WU FRANK;XU GUOYOU;OR YAT S.;WANG ZHE
分类号 C07D245/00;A01N43/00;A61K31/33;A61K38/12;C07D487/00;C07K5/083;C07K5/12;E05F15/20;G01S7/52;G01S15/04 主分类号 C07D245/00
代理机构 代理人
主权项
地址